Abstract
背景与目的对初治后复发或转移性非小细胞肺癌（non-small cell lung cancer, NSCLC）患者的治疗，需引入新的二线药物及治疗方法。培美曲塞为多靶点抗叶酸化疗药物，近来多用于NSCLC的治疗。本研究旨在探讨培美曲塞联合顺铂或卡铂方案治疗复发或转移性NSCLC的疗效以及不良反应。方法经病理学或细胞学确诊的复发或转移性晚期NSCLC患者63例，其中男性40例，女性23例，中位年龄62岁。培美曲塞500 mg/m2第1天+顺铂30 mg/m2第1、2、3天或卡铂300 mg/m2第1天静脉滴注，每3周重复。评价疗效及不良反应。结果63例中完全缓解1例，部分缓解5例，稳定36例，进展21例，疾病控制率为66.7%（42/63），中位生存期为9.0个月。中位无疾病进展时间为5.0个月，其中鳞癌为3.0个月，腺癌为5.5个月，非鳞癌优于鳞癌，差异有统计学意义（P=0.017）。主要不良反应为粒细胞下降、贫血和胃肠道反应。结论培美曲塞联合顺铂或卡铂方案治疗复发或转移性NSCLC疗效确切，对非鳞癌更具有治疗优势。不良反应发生率低，耐受性较好。
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
